416 related articles for article (PubMed ID: 31865479)
1. Vessel co-option and resistance to anti-angiogenic therapy.
Kuczynski EA; Reynolds AR
Angiogenesis; 2020 Feb; 23(1):55-74. PubMed ID: 31865479
[TBL] [Abstract][Full Text] [Related]
2. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
Bridgeman VL; Vermeulen PB; Foo S; Bilecz A; Daley F; Kostaras E; Nathan MR; Wan E; Frentzas S; Schweiger T; Hegedus B; Hoetzenecker K; Renyi-Vamos F; Kuczynski EA; Vasudev NS; Larkin J; Gore M; Dvorak HF; Paku S; Kerbel RS; Dome B; Reynolds AR
J Pathol; 2017 Feb; 241(3):362-374. PubMed ID: 27859259
[TBL] [Abstract][Full Text] [Related]
3. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.
Frentzas S; Simoneau E; Bridgeman VL; Vermeulen PB; Foo S; Kostaras E; Nathan M; Wotherspoon A; Gao ZH; Shi Y; Van den Eynden G; Daley F; Peckitt C; Tan X; Salman A; Lazaris A; Gazinska P; Berg TJ; Eltahir Z; Ritsma L; Van Rheenen J; Khashper A; Brown G; Nystrom H; Sund M; Van Laere S; Loyer E; Dirix L; Cunningham D; Metrakos P; Reynolds AR
Nat Med; 2016 Nov; 22(11):1294-1302. PubMed ID: 27748747
[TBL] [Abstract][Full Text] [Related]
4. The emerging roles of circular RNAs in vessel co-option and vasculogenic mimicry: clinical insights for anti-angiogenic therapy in cancers.
Shao Y; Lu B
Cancer Metastasis Rev; 2022 Mar; 41(1):173-191. PubMed ID: 34664157
[TBL] [Abstract][Full Text] [Related]
5. Tumour angiogenesis, anti-angiogenic therapy and chemotherapeutic resistance.
Mander KA; Finnie JW
Aust Vet J; 2018 Oct; 96(10):371-378. PubMed ID: 30255577
[TBL] [Abstract][Full Text] [Related]
6. Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?
Donnem T; Hu J; Ferguson M; Adighibe O; Snell C; Harris AL; Gatter KC; Pezzella F
Cancer Med; 2013 Aug; 2(4):427-36. PubMed ID: 24156015
[TBL] [Abstract][Full Text] [Related]
7. Pathological features of vessel co-option versus sprouting angiogenesis.
Latacz E; Caspani E; Barnhill R; Lugassy C; Verhoef C; Grünhagen D; Van Laere S; Fernández Moro C; Gerling M; Dirix M; Dirix LY; Vermeulen PB
Angiogenesis; 2020 Feb; 23(1):43-54. PubMed ID: 31655928
[TBL] [Abstract][Full Text] [Related]
8. Modes of resistance to anti-angiogenic therapy.
Bergers G; Hanahan D
Nat Rev Cancer; 2008 Aug; 8(8):592-603. PubMed ID: 18650835
[TBL] [Abstract][Full Text] [Related]
9. Vessel co-option in cancer.
Kuczynski EA; Vermeulen PB; Pezzella F; Kerbel RS; Reynolds AR
Nat Rev Clin Oncol; 2019 Aug; 16(8):469-493. PubMed ID: 30816337
[TBL] [Abstract][Full Text] [Related]
10. Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy.
Elebiyo TC; Rotimi D; Evbuomwan IO; Maimako RF; Iyobhebhe M; Ojo OA; Oluba OM; Adeyemi OS
Cancer Treat Res Commun; 2022; 32():100620. PubMed ID: 35964475
[TBL] [Abstract][Full Text] [Related]
11. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies.
Rapisarda A; Melillo G
Drug Resist Updat; 2009 Jun; 12(3):74-80. PubMed ID: 19394890
[TBL] [Abstract][Full Text] [Related]
12. Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?
Helfrich I; Schadendorf D
Mol Oncol; 2011 Apr; 5(2):137-49. PubMed ID: 21345752
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?
Coelho AL; Gomes MP; Catarino RJ; Rolfo C; Lopes AM; Medeiros RM; Araújo AM
Oncotarget; 2017 Jun; 8(24):39795-39804. PubMed ID: 26950275
[TBL] [Abstract][Full Text] [Related]
14. Broad targeting of angiogenesis for cancer prevention and therapy.
Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D; Chen YC; Honoki K; Fujii H; Georgakilas AG; Nowsheen S; Amedei A; Niccolai E; Amin A; Ashraf SS; Helferich B; Yang X; Guha G; Bhakta D; Ciriolo MR; Aquilano K; Chen S; Halicka D; Mohammed SI; Azmi AS; Bilsland A; Keith WN; Jensen LD
Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S224-S243. PubMed ID: 25600295
[TBL] [Abstract][Full Text] [Related]
15. Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation.
Qian CN; Tan MH; Yang JP; Cao Y
Chin J Cancer; 2016 Jan; 35():10. PubMed ID: 26747273
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of angiogenesis and the angiogenesis/invasion shift.
Bikfalvi A; Moenner M; Javerzat S; North S; Hagedorn M
Biochem Soc Trans; 2011 Dec; 39(6):1560-4. PubMed ID: 22103487
[TBL] [Abstract][Full Text] [Related]
17. Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma.
Kuczynski EA; Kerbel RS
Chin J Cancer; 2016 Nov; 35(1):97. PubMed ID: 27887628
[TBL] [Abstract][Full Text] [Related]
18. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
19. Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas.
Wong ML; Prawira A; Kaye AH; Hovens CM
J Clin Neurosci; 2009 Sep; 16(9):1119-30. PubMed ID: 19556134
[TBL] [Abstract][Full Text] [Related]
20. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
